Showing results (91-100 of 150) with videos related to
Sort By:
Pageof 15
Acta Otorhinolaryngologica Italica : Organo Ufficiale Della Societa Italiana Di Otorinolaringologia E Chirurgia Cervico-Facciale|May 19, 2026
Is there a role for adjuvant radiotherapy after partial laryngectomy? A propensity score matched analysisLiliana Belgioia, Ida D'Onofrio, Marta Filauro, et al.Breast Cancer Research : BCR|May 31, 2019
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trialLorenzo Rossi, Chiara Biagioni, Amelia McCartney, et al.Lung Cancer (Amsterdam, Netherlands)|December 19, 2024
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016Francesco Gelsomino, Luca Boni, Marcello Tiseo, et al.NPJ Breast Cancer|December 18, 2024
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancerLinda Cucciniello, Eva Blondeaux, Claudia Bighin, et al.The Oncologist|December 18, 2020
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based AnalysisFilippo Pietrantonio, Giovanni Fucà, Daniele Rossini, et al.BMC Cancer|June 11, 2017
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO groupChiara Cremolini, Federica Marmorino, Fotios Loupakis, et al.BMC Cancer|July 24, 2020
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancerCarlotta Antoniotti, Beatrice Borelli, Daniele Rossini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trialCarlo Aschele, Luca Cionini, Sara Lonardi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for NeuroblastomaBruno De Bernardi, Brigitte Nicolas, Luca Boni, et al.Journal of the National Cancer Institute|February 5, 2025
Prognostic implications of risk definitions from the monarchE and NATALEE trialsLuca Arecco, Eva Blondeaux, Marco Bruzzone, et al.Pageof 15